[99mTc]duramycin for cell death imaging: Impact of kit formulation, purification and species difference
[99mTc]duramycin is a SPECT tracer for cell death imaging. We evaluated the impact of kit formulation, purification and species difference on the pharmacokinetic profile and cell death targeting properties of [99mTc]duramycin in order to define the optimal conditions for (pre-)clinical use.
Gespeichert in:
| Autor*in: |
Palmieri, Luca [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018 |
|---|
| Umfang: |
9 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time - Michaud, Jason E. ELSEVIER, 2023, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:56 ; year:2018 ; pages:1-9 ; extent:9 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.nucmedbio.2017.08.005 |
|---|
| Katalog-ID: |
ELV04136368X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV04136368X | ||
| 003 | DE-627 | ||
| 005 | 20230624084456.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180726s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nucmedbio.2017.08.005 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000063A.pica |
| 035 | |a (DE-627)ELV04136368X | ||
| 035 | |a (ELSEVIER)S0969-8051(17)30084-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 |a 570 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 570 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.88 |2 bkl | ||
| 100 | 1 | |a Palmieri, Luca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a [99mTc]duramycin for cell death imaging: Impact of kit formulation, purification and species difference |
| 264 | 1 | |c 2018 | |
| 300 | |a 9 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a [99mTc]duramycin is a SPECT tracer for cell death imaging. We evaluated the impact of kit formulation, purification and species difference on the pharmacokinetic profile and cell death targeting properties of [99mTc]duramycin in order to define the optimal conditions for (pre-)clinical use. | ||
| 700 | 1 | |a Elvas, Filipe |4 oth | |
| 700 | 1 | |a Vangestel, Christel |4 oth | |
| 700 | 1 | |a Pak, Koon |4 oth | |
| 700 | 1 | |a Gray, Brian |4 oth | |
| 700 | 1 | |a Stroobants, Sigrid |4 oth | |
| 700 | 1 | |a Staelens, Steven |4 oth | |
| 700 | 1 | |a wyffels, Leonie |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Michaud, Jason E. ELSEVIER |t Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time |d 2023 |g Amsterdam [u.a.] |w (DE-627)ELV010596976 |
| 773 | 1 | 8 | |g volume:56 |g year:2018 |g pages:1-9 |g extent:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.nucmedbio.2017.08.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.88 |j Urologie |j Nephrologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 56 |j 2018 |h 1-9 |g 9 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
l p lp |
|---|---|
| matchkey_str |
palmierilucaelvasfilipevangestelchristel:2018----:9tdrmcnocldahmgnipcoktomltoprfc |
| hierarchy_sort_str |
2018 |
| bklnumber |
44.88 |
| publishDate |
2018 |
| allfields |
10.1016/j.nucmedbio.2017.08.005 doi GBV00000000000063A.pica (DE-627)ELV04136368X (ELSEVIER)S0969-8051(17)30084-7 DE-627 ger DE-627 rakwb eng 610 570 610 DE-600 570 DE-600 610 VZ 44.88 bkl Palmieri, Luca verfasserin aut [99mTc]duramycin for cell death imaging: Impact of kit formulation, purification and species difference 2018 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier [99mTc]duramycin is a SPECT tracer for cell death imaging. We evaluated the impact of kit formulation, purification and species difference on the pharmacokinetic profile and cell death targeting properties of [99mTc]duramycin in order to define the optimal conditions for (pre-)clinical use. Elvas, Filipe oth Vangestel, Christel oth Pak, Koon oth Gray, Brian oth Stroobants, Sigrid oth Staelens, Steven oth wyffels, Leonie oth Enthalten in Elsevier Science Michaud, Jason E. ELSEVIER Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time 2023 Amsterdam [u.a.] (DE-627)ELV010596976 volume:56 year:2018 pages:1-9 extent:9 https://doi.org/10.1016/j.nucmedbio.2017.08.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.88 Urologie Nephrologie VZ AR 56 2018 1-9 9 045F 610 |
| spelling |
10.1016/j.nucmedbio.2017.08.005 doi GBV00000000000063A.pica (DE-627)ELV04136368X (ELSEVIER)S0969-8051(17)30084-7 DE-627 ger DE-627 rakwb eng 610 570 610 DE-600 570 DE-600 610 VZ 44.88 bkl Palmieri, Luca verfasserin aut [99mTc]duramycin for cell death imaging: Impact of kit formulation, purification and species difference 2018 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier [99mTc]duramycin is a SPECT tracer for cell death imaging. We evaluated the impact of kit formulation, purification and species difference on the pharmacokinetic profile and cell death targeting properties of [99mTc]duramycin in order to define the optimal conditions for (pre-)clinical use. Elvas, Filipe oth Vangestel, Christel oth Pak, Koon oth Gray, Brian oth Stroobants, Sigrid oth Staelens, Steven oth wyffels, Leonie oth Enthalten in Elsevier Science Michaud, Jason E. ELSEVIER Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time 2023 Amsterdam [u.a.] (DE-627)ELV010596976 volume:56 year:2018 pages:1-9 extent:9 https://doi.org/10.1016/j.nucmedbio.2017.08.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.88 Urologie Nephrologie VZ AR 56 2018 1-9 9 045F 610 |
| allfields_unstemmed |
10.1016/j.nucmedbio.2017.08.005 doi GBV00000000000063A.pica (DE-627)ELV04136368X (ELSEVIER)S0969-8051(17)30084-7 DE-627 ger DE-627 rakwb eng 610 570 610 DE-600 570 DE-600 610 VZ 44.88 bkl Palmieri, Luca verfasserin aut [99mTc]duramycin for cell death imaging: Impact of kit formulation, purification and species difference 2018 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier [99mTc]duramycin is a SPECT tracer for cell death imaging. We evaluated the impact of kit formulation, purification and species difference on the pharmacokinetic profile and cell death targeting properties of [99mTc]duramycin in order to define the optimal conditions for (pre-)clinical use. Elvas, Filipe oth Vangestel, Christel oth Pak, Koon oth Gray, Brian oth Stroobants, Sigrid oth Staelens, Steven oth wyffels, Leonie oth Enthalten in Elsevier Science Michaud, Jason E. ELSEVIER Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time 2023 Amsterdam [u.a.] (DE-627)ELV010596976 volume:56 year:2018 pages:1-9 extent:9 https://doi.org/10.1016/j.nucmedbio.2017.08.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.88 Urologie Nephrologie VZ AR 56 2018 1-9 9 045F 610 |
| allfieldsGer |
10.1016/j.nucmedbio.2017.08.005 doi GBV00000000000063A.pica (DE-627)ELV04136368X (ELSEVIER)S0969-8051(17)30084-7 DE-627 ger DE-627 rakwb eng 610 570 610 DE-600 570 DE-600 610 VZ 44.88 bkl Palmieri, Luca verfasserin aut [99mTc]duramycin for cell death imaging: Impact of kit formulation, purification and species difference 2018 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier [99mTc]duramycin is a SPECT tracer for cell death imaging. We evaluated the impact of kit formulation, purification and species difference on the pharmacokinetic profile and cell death targeting properties of [99mTc]duramycin in order to define the optimal conditions for (pre-)clinical use. Elvas, Filipe oth Vangestel, Christel oth Pak, Koon oth Gray, Brian oth Stroobants, Sigrid oth Staelens, Steven oth wyffels, Leonie oth Enthalten in Elsevier Science Michaud, Jason E. ELSEVIER Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time 2023 Amsterdam [u.a.] (DE-627)ELV010596976 volume:56 year:2018 pages:1-9 extent:9 https://doi.org/10.1016/j.nucmedbio.2017.08.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.88 Urologie Nephrologie VZ AR 56 2018 1-9 9 045F 610 |
| allfieldsSound |
10.1016/j.nucmedbio.2017.08.005 doi GBV00000000000063A.pica (DE-627)ELV04136368X (ELSEVIER)S0969-8051(17)30084-7 DE-627 ger DE-627 rakwb eng 610 570 610 DE-600 570 DE-600 610 VZ 44.88 bkl Palmieri, Luca verfasserin aut [99mTc]duramycin for cell death imaging: Impact of kit formulation, purification and species difference 2018 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier [99mTc]duramycin is a SPECT tracer for cell death imaging. We evaluated the impact of kit formulation, purification and species difference on the pharmacokinetic profile and cell death targeting properties of [99mTc]duramycin in order to define the optimal conditions for (pre-)clinical use. Elvas, Filipe oth Vangestel, Christel oth Pak, Koon oth Gray, Brian oth Stroobants, Sigrid oth Staelens, Steven oth wyffels, Leonie oth Enthalten in Elsevier Science Michaud, Jason E. ELSEVIER Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time 2023 Amsterdam [u.a.] (DE-627)ELV010596976 volume:56 year:2018 pages:1-9 extent:9 https://doi.org/10.1016/j.nucmedbio.2017.08.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.88 Urologie Nephrologie VZ AR 56 2018 1-9 9 045F 610 |
| language |
English |
| source |
Enthalten in Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time Amsterdam [u.a.] volume:56 year:2018 pages:1-9 extent:9 |
| sourceStr |
Enthalten in Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time Amsterdam [u.a.] volume:56 year:2018 pages:1-9 extent:9 |
| format_phy_str_mv |
Article |
| bklname |
Urologie Nephrologie |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time |
| authorswithroles_txt_mv |
Palmieri, Luca @@aut@@ Elvas, Filipe @@oth@@ Vangestel, Christel @@oth@@ Pak, Koon @@oth@@ Gray, Brian @@oth@@ Stroobants, Sigrid @@oth@@ Staelens, Steven @@oth@@ wyffels, Leonie @@oth@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
ELV010596976 |
| dewey-sort |
3610 |
| id |
ELV04136368X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV04136368X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624084456.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.nucmedbio.2017.08.005</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000063A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV04136368X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0969-8051(17)30084-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield><subfield code="a">570</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.88</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Palmieri, Luca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">[99mTc]duramycin for cell death imaging: Impact of kit formulation, purification and species difference</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">[99mTc]duramycin is a SPECT tracer for cell death imaging. We evaluated the impact of kit formulation, purification and species difference on the pharmacokinetic profile and cell death targeting properties of [99mTc]duramycin in order to define the optimal conditions for (pre-)clinical use.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Elvas, Filipe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vangestel, Christel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pak, Koon</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gray, Brian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stroobants, Sigrid</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Staelens, Steven</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">wyffels, Leonie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Michaud, Jason E. ELSEVIER</subfield><subfield code="t">Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time</subfield><subfield code="d">2023</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV010596976</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:56</subfield><subfield code="g">year:2018</subfield><subfield code="g">pages:1-9</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.nucmedbio.2017.08.005</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.88</subfield><subfield code="j">Urologie</subfield><subfield code="j">Nephrologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">56</subfield><subfield code="j">2018</subfield><subfield code="h">1-9</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Palmieri, Luca |
| spellingShingle |
Palmieri, Luca ddc 610 ddc 570 bkl 44.88 [99mTc]duramycin for cell death imaging: Impact of kit formulation, purification and species difference |
| authorStr |
Palmieri, Luca |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV010596976 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 570 - Life sciences; biology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 570 610 DE-600 570 DE-600 610 VZ 44.88 bkl [99mTc]duramycin for cell death imaging: Impact of kit formulation, purification and species difference |
| topic |
ddc 610 ddc 570 bkl 44.88 |
| topic_unstemmed |
ddc 610 ddc 570 bkl 44.88 |
| topic_browse |
ddc 610 ddc 570 bkl 44.88 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
f e fe c v cv k p kp b g bg s s ss s s ss l w lw |
| hierarchy_parent_title |
Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time |
| hierarchy_parent_id |
ELV010596976 |
| dewey-tens |
610 - Medicine & health 570 - Life sciences; biology |
| hierarchy_top_title |
Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV010596976 |
| title |
[99mTc]duramycin for cell death imaging: Impact of kit formulation, purification and species difference |
| ctrlnum |
(DE-627)ELV04136368X (ELSEVIER)S0969-8051(17)30084-7 |
| title_full |
[99mTc]duramycin for cell death imaging: Impact of kit formulation, purification and species difference |
| author_sort |
Palmieri, Luca |
| journal |
Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time |
| journalStr |
Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
1 |
| author_browse |
Palmieri, Luca |
| container_volume |
56 |
| physical |
9 |
| class |
610 570 610 DE-600 570 DE-600 610 VZ 44.88 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Palmieri, Luca |
| doi_str_mv |
10.1016/j.nucmedbio.2017.08.005 |
| dewey-full |
610 570 |
| title_sort |
[99mtc]duramycin for cell death imaging: impact of kit formulation, purification and species difference |
| title_auth |
[99mTc]duramycin for cell death imaging: Impact of kit formulation, purification and species difference |
| abstract |
[99mTc]duramycin is a SPECT tracer for cell death imaging. We evaluated the impact of kit formulation, purification and species difference on the pharmacokinetic profile and cell death targeting properties of [99mTc]duramycin in order to define the optimal conditions for (pre-)clinical use. |
| abstractGer |
[99mTc]duramycin is a SPECT tracer for cell death imaging. We evaluated the impact of kit formulation, purification and species difference on the pharmacokinetic profile and cell death targeting properties of [99mTc]duramycin in order to define the optimal conditions for (pre-)clinical use. |
| abstract_unstemmed |
[99mTc]duramycin is a SPECT tracer for cell death imaging. We evaluated the impact of kit formulation, purification and species difference on the pharmacokinetic profile and cell death targeting properties of [99mTc]duramycin in order to define the optimal conditions for (pre-)clinical use. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
[99mTc]duramycin for cell death imaging: Impact of kit formulation, purification and species difference |
| url |
https://doi.org/10.1016/j.nucmedbio.2017.08.005 |
| remote_bool |
true |
| author2 |
Elvas, Filipe Vangestel, Christel Pak, Koon Gray, Brian Stroobants, Sigrid Staelens, Steven wyffels, Leonie |
| author2Str |
Elvas, Filipe Vangestel, Christel Pak, Koon Gray, Brian Stroobants, Sigrid Staelens, Steven wyffels, Leonie |
| ppnlink |
ELV010596976 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.nucmedbio.2017.08.005 |
| up_date |
2024-07-06T19:55:14.202Z |
| _version_ |
1803860798817173504 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV04136368X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624084456.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.nucmedbio.2017.08.005</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000063A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV04136368X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0969-8051(17)30084-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield><subfield code="a">570</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.88</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Palmieri, Luca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">[99mTc]duramycin for cell death imaging: Impact of kit formulation, purification and species difference</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">[99mTc]duramycin is a SPECT tracer for cell death imaging. We evaluated the impact of kit formulation, purification and species difference on the pharmacokinetic profile and cell death targeting properties of [99mTc]duramycin in order to define the optimal conditions for (pre-)clinical use.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Elvas, Filipe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vangestel, Christel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pak, Koon</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gray, Brian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stroobants, Sigrid</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Staelens, Steven</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">wyffels, Leonie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Michaud, Jason E. ELSEVIER</subfield><subfield code="t">Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time</subfield><subfield code="d">2023</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV010596976</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:56</subfield><subfield code="g">year:2018</subfield><subfield code="g">pages:1-9</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.nucmedbio.2017.08.005</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.88</subfield><subfield code="j">Urologie</subfield><subfield code="j">Nephrologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">56</subfield><subfield code="j">2018</subfield><subfield code="h">1-9</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.397299 |